The companies will join forces to advance the
use of precision medicine on a global scale
BOSTON and ROLLE,
Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS
(Nasdaq: SOPH), a cloud-native software company in the healthcare
space and a leader in data-driven medicine, today announced a
strategic partnership with Strand Life Sciences, a pioneer in
bioinformatics and diagnostics, to deliver innovative solutions
that will fuel the use of precision medicine globally. The new
collaboration will leverage the industry-leading strengths from
both companies to provide access to advanced genomics technologies,
cutting-edge bioinformatics services and innovative diagnostics
solutions.
Headquartered in Bangalore,
India, Strand is a life sciences technology company with
expertise in bioinformatics, laboratory assays, clinical research
and software development. It supports an expansive global customer
base with its custom applications that help expand and improve the
use of precision medicine worldwide.
"We are excited about our collaboration with SOPHiA GENETICS
that will aim to take our combined expertise in bioinformatics to
help partner organizations across the globe deliver next-generation
precision medicine to improve patient care," said Ramesh Hariharan, CEO and Co-Founder of
Strand.
Through the broad-ranging collaboration between SOPHiA GENETICS
and Strand, the two companies will use their bioinformatics
expertise to expand the ability to accurately analyze key
healthcare data and facilitate the use of data-driven
decision-making globally. SOPHiA GENETICS will provide support via
the decentralized SOPHiA DDM™ Platform and Strand via
its curated variant databases and bioinformatics solutions
expertise, and the companies will collaborate on strategic test
co-development, among other initiatives, that will look to improve
health outcomes in India and
globally.
"Strand and SOPHiA GENETICS have a shared vision to improve
patient health outcomes through precision medicine," said Jurgi
Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS. "It is
imperative that healthcare organizations have the ability to
process previously siloed data in a timely manner and receive
highly accurate results, which facilitate rapid and effective
treatments for cancers and rare diseases. This strategic
partnership will further enable innovation."
The SOPHiA DDM™ Platform is designed to compute a wide array of
genomic variants and continually hone machine learning algorithms.
With their sophisticated technologies and bioinformatics expertise,
SOPHiA GENETICS and Strand will jointly deepen their value
propositions.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and
Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care for life sciences research. It is the creator of the SOPHiA
DDM™ Platform, a cloud-native platform capable of analyzing data
and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
About Strand Life Sciences
Strand
Life Sciences Private Limited is a genomics-based research and
diagnostics company that combines a long track record
in bioinformatics with cutting-edge laboratory assays and a vast
hospital partner network to drive newer generations of
patient care. Strand's customers include global instrument,
diagnostic and pharmaceutical companies. Strand is
also a pioneer of genomic testing in India. Strand's long global
bioinformatics track record makes it the most trusted company
for genomic diagnostics in the areas of oncology, rare
diseases, women's health, and infectious diseases.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-and-strand-life-sciences-announce-new-strategic-partnership-302107640.html